Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma

This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting BCMA or GPRC5D or both sequentially in the treatment of Relapsed/ Refractory Multiple myeloma

Trial Details

NCT ID
NCT07032129
Phase
PHASE1 / PHASE2
Sponsor
Essen Biotech
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • BCMA/GPRC5D CAR-T cells
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Expected survival time ≥3 months;
  • Subjects with recurrent/refractory Multiple Myeloma who have failed standard treatment or lack effective treatment, Including but not limited to sy…
  • Histological evidence of non-suppurative destructive cholangitis and small bile duct destruction.
  • Liver and kidney function, cardiopulmonary function meet the following requirements:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →